Revvity, Inc. (RVTY)

Market Cap	10.65B
Revenue (ttm)	2.80B
Net Income (ttm)	285.20M
Shares Out	116.07M
EPS (ttm)	2.37
PE Ratio	39.68
Forward PE	17.84
Dividend	$0.28 (0.31%)
Ex-Dividend Date	Oct 17, 2025

Volume	961,695
Open	91.31
Previous Close	91.19
Day's Range	90.41 - 92.24
52-Week Range	81.36 - 129.50
Beta	0.99
Analysts	Buy
Price Target	117.21 (+27.72%)
Earnings Date	Oct 27, 2025

About RVTY

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and dise...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1937
• Employees: 11,000
• Stock Exchange: NYSE
• Ticker Symbol: RVTY
• Website: https://www.revvity.com

Financial Performance

In 2024, Revvity's revenue was $2.76 billion, an increase of 0.16% compared to the previous year's $2.75 billion. Earnings were $270.39 million, a decrease of -60.99%.

Analyst Summary

According to 14 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $117.21, which is an increase of 27.72% from the latest price.

Price Target

$117.21

(27.72% upside)

Analyst Consensus: Buy